CureVac在与BioNTech SE的诉讼中获得欧洲专利局的积极有效性裁决-动脉网

CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE

D-Pharm 等信源发布 2025-03-28 17:13



可切换为仅中文







CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), announced that the European Patent Office (EPO) has confirmed the validity of CureVac’s European patent EP 3 708 668 B1 subject to amendments to specify the scope of protection.

CureVac N.V. 是一家全球生物制药公司，致力于开发基于信使核糖核酸 (“mRNA”) 的新型变革性药物，该公司宣布欧洲专利局 (EPO) 已确认 CureVac 的欧洲专利 EP 3 708 668 B1 的有效性，但需对其进行修改以明确保护范围。

Following the hearing, the opposition division largely dismissed the opposition originally filed by BioNTech SE in April 2023 challenging the patent’s validity and maintained the patent in amended form..

在听证会之后，反对部门基本上驳回了 BioNTech SE 于 2023 年 4 月最初提出的质疑该专利有效性的反对意见，并以修改后的形式维持了该专利。

The ruling represents a major milestone in the ongoing patent dispute between CureVac and BioNTech in Germany, which involves a total of six intellectual property rights. Following the ruling, the Regional Court Düsseldorf will decide whether the patent in its amended form has been infringed. An infringement hearing is scheduled for July 1, 2025.

该裁决代表了 CureVac 与 BioNTech 在德国持续进行的专利纠纷中的一个重要里程碑，该纠纷共涉及六项知识产权。裁决之后，杜塞尔多夫地区法院将决定修改后的专利是否已被侵权。侵权听证会定于 2025 年 7 月 1 日举行。

A positive infringement decision would trigger proceedings to assess damages in the same court..

一项肯定的侵权决定将触发同一法院评估损害赔偿的程序。

“We welcome the decision of the EPO to uphold EP 3 708 668 B1 and remain confident that the patent is infringed in its amended form. Today’s decision marks an important step on our path that we expect will lead to recognition of CureVac’s major contribution to safe and efficacious COVID-19 vaccines as the earliest pioneer in mRNA technology,” said Dr.

“我们欢迎欧洲专利局（EPO）维持专利EP 3 708 668 B1的决定，并坚信修订后的专利仍然受到侵犯。今天的决定标志着我们在预期道路上迈出了重要一步，这将确认CureVac作为mRNA技术最早先驱者对安全有效的COVID-19疫苗的重大贡献，”博士表示。

Alexander Zehnder, Chief Executive Officer of CureVac. “This effort is a multi-step process in Europe and the U.S. We remain determined to have our contributions to the field of mRNA technology acknowledged and fairly compensated, and to continue making advances that expand the frontiers of mRNA-based medicines.”.

CureVac首席执行官亚历山大·泽恩德表示：“这一努力是欧洲和美国的多步骤过程。我们仍然决心在mRNA技术领域获得应有的认可和公平补偿，并继续推动扩展基于mRNA药物的前沿发展。”

EP 3 708 668 B1 describes a foundational invention of CureVac, called split poly-A tail technology, which enhances medical efficacy by improving expression of the protein encoded on an mRNA construct.

EP 3 708 668 B1 描述了 CureVac 的一项基础发明，称为分裂型多聚腺苷酸尾技术，该技术通过提高 mRNA 构建体上编码蛋白的表达来增强医学疗效。

CureVac is represented in Germany by Oliver Jan Jüngst from Bird & Bird LLP and Andreas Graf von Stosch from Graf von Stosch Patentanwaltsgesellschaft and represented in the U.S. by Mark H. Izraelewicz from Marshall, Gerstein & Borun LLP and John M. Erbach from Spotts Fain, PC.

CureVac在德国由Bird & Bird LLP的奥利弗·扬·容斯特和Graf von Stosch Patentanwaltsgesellschaft的安德烈亚斯·格拉夫·冯·斯托施代表，在美国由Marshall, Gerstein & Borun LLP的马克·H·伊扎列维奇和Spotts Fain, PC的约翰·M·厄巴赫代表。

https://www.bionity.com/en/news/1185910/curevac-receives-positive-validity-decision-from-european-patent-office-in-litigation-against-biontech-se.html

WACKER Opens mRNA Competence Center in Halle an der Saale, Germany

瓦克在德国哈尔萨勒开设mRNA能力中心

Expansion enables the company to produce mRNA actives on a large scale going forward

扩张使公司能够在未来大规模生产mRNA活性物质

Read news

阅读新闻